Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BAXTER MARKETING AGREEMENT WITH STERIS LABS

Executive Summary

BAXTER MARKETING AGREEMENT WITH STERIS LABS initially covers 30 generic injectable products and could be expanded to include 100 products, Steris said. "The agreement combines the sales and marketing strengths of Baxter with the state-of-the-art manufacturing capabilities of Steris," Steris President Jim McGee stated in a recent press release. Under the open-ended agreement, Steris will manufacture small-volume parenteral generic drug products under the Baxter label. Drugs will typically be packaged in vials and ampules ranging from 1 ml to 20 ml, according to the company. Established in December 1986 with the purchase of Carter-Glogau assets from Revco, Steris is a wholly owned subsidiary of Schein Pharmaceutical. The firm manufactures and markets a wide range of injectables, including suspensions and lyophilized products, as well as topical ophthalmics and otics, from its 120,000 sq. ft. facility in Phoenix, Arizona. Steris has a dedicated marketing force of 10 reps.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel